JP2004522747A - ３，５−ジヨードチロプロピオン酸を用いた慢性心不全および／または高コレステロールの治療方法と、この酸の製造方法 - Google Patents

３，５−ジヨードチロプロピオン酸を用いた慢性心不全および／または高コレステロールの治療方法と、この酸の製造方法 Download PDF

Info

Publication number
JP2004522747A
JP2004522747A JP2002560585A JP2002560585A JP2004522747A JP 2004522747 A JP2004522747 A JP 2004522747A JP 2002560585 A JP2002560585 A JP 2002560585A JP 2002560585 A JP2002560585 A JP 2002560585A JP 2004522747 A JP2004522747 A JP 2004522747A
Authority
JP
Japan
Prior art keywords
acid
diiodothyropropionic
administered
formulation
ditpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002560585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004522747A5 (https=
Inventor
ゴールドマン，スティーヴン
ペノック，グレゴリー，ディー．
モルキン，ユージン
バール，ジョセフ，ジェイ．
Original Assignee
ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ filed Critical ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ
Publication of JP2004522747A publication Critical patent/JP2004522747A/ja
Publication of JP2004522747A5 publication Critical patent/JP2004522747A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2002560585A 2001-01-31 2002-01-31 ３，５−ジヨードチロプロピオン酸を用いた慢性心不全および／または高コレステロールの治療方法と、この酸の製造方法 Pending JP2004522747A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/774,994 US6534676B2 (en) 2001-01-31 2001-01-31 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
PCT/US2002/003162 WO2002060389A2 (en) 2001-01-31 2002-01-31 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same

Publications (2)

Publication Number Publication Date
JP2004522747A true JP2004522747A (ja) 2004-07-29
JP2004522747A5 JP2004522747A5 (https=) 2005-12-22

Family

ID=25102976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002560585A Pending JP2004522747A (ja) 2001-01-31 2002-01-31 ３，５−ジヨードチロプロピオン酸を用いた慢性心不全および／または高コレステロールの治療方法と、この酸の製造方法

Country Status (7)

Country Link
US (1) US6534676B2 (https=)
EP (1) EP1432310A4 (https=)
JP (1) JP2004522747A (https=)
AU (1) AU2002243801B2 (https=)
CA (1) CA2436421C (https=)
MX (1) MXPA03006855A (https=)
WO (1) WO2002060389A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513461A (ja) * 2004-09-15 2008-05-01 オードウェイ リサーチ インスティテュート 血管形成を促進する甲状腺ホルモンアナログ
WO2009028608A1 (ja) 2007-08-31 2009-03-05 Mitsubishi Gas Chemical Company, Inc. オルト位がヨウ素置換されたフェノール誘導体の製造方法
JP2017507929A (ja) * 2014-02-10 2017-03-23 フレッド ハッチンソン キャンサー リサーチ センター 心臓発作及び虚血損傷のハロゲン治療

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716877B2 (en) * 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US7504435B2 (en) * 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
AU2004273986B2 (en) * 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
AU2007353426A1 (en) * 2006-12-22 2008-11-20 Albany College Of Pharmacy And Health Sciences Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2008106213A1 (en) * 2007-02-27 2008-09-04 Titan Pharmaceuticals, Inc. Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome.
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
CA2765792C (en) 2009-06-17 2017-03-28 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
JP7074749B2 (ja) 2016-06-07 2022-05-24 ナノファーマシューティカルズ エルエルシー αｖβ３インテグリン甲状腺アンタゴニストにコンジュゲートした非開裂性ポリマー
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
WO2024015764A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC 3,5-diiodothyropropionic acid compositions and methods of use thereof
US12390432B2 (en) 2022-07-11 2025-08-19 PriZm, LLC Methods for treating allan-herndon-dudley syndrome
WO2024015763A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC Methods and formulations for prenatal treatment of allan-herndon-dudley syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149153A (en) * 1961-12-05 1964-09-15 Smith Kline French Lab 3'-substituted-3, 5-diiodothyronine and salts thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US812140A (en) * 1901-06-14 1906-02-06 Perry E Kent Gun-barrel for pistols, rifles, and ordnance.
US2803654A (en) 1955-06-24 1957-08-20 Baxter Laboratories Inc Preparation of thyroxine products
DE1078582B (de) * 1958-10-29 1960-03-31 Hoechst Ag Verfahren zur Herstellung substituierter Thyropropionsaeuren
US3102136A (en) * 1959-06-24 1963-08-27 Warner Lambert Pharmaceutical Process of preparing diiodinated analogs of thyronine
US5158978A (en) 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
DE69328838T2 (de) * 1992-03-13 2000-10-12 Sepracor Inc., Marlborough Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149153A (en) * 1961-12-05 1964-09-15 Smith Kline French Lab 3'-substituted-3, 5-diiodothyronine and salts thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513461A (ja) * 2004-09-15 2008-05-01 オードウェイ リサーチ インスティテュート 血管形成を促進する甲状腺ホルモンアナログ
WO2009028608A1 (ja) 2007-08-31 2009-03-05 Mitsubishi Gas Chemical Company, Inc. オルト位がヨウ素置換されたフェノール誘導体の製造方法
JP2017507929A (ja) * 2014-02-10 2017-03-23 フレッド ハッチンソン キャンサー リサーチ センター 心臓発作及び虚血損傷のハロゲン治療
JP2019194265A (ja) * 2014-02-10 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター 心臓発作及び虚血損傷のハロゲン治療

Also Published As

Publication number Publication date
MXPA03006855A (es) 2004-03-12
WO2002060389A3 (en) 2004-04-15
CA2436421C (en) 2011-06-14
US20020151594A1 (en) 2002-10-17
WO2002060389A2 (en) 2002-08-08
CA2436421A1 (en) 2002-08-08
AU2002243801B2 (en) 2006-12-07
EP1432310A4 (en) 2006-06-21
US6534676B2 (en) 2003-03-18
EP1432310A2 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
JP2004522747A (ja) ３，５−ジヨードチロプロピオン酸を用いた慢性心不全および／または高コレステロールの治療方法と、この酸の製造方法
AU2002243801A1 (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
KR910004572B1 (ko) 경구용 당뇨병 치료제 제형의 제조방법
DE69313849T2 (de) Pharmazeutische zusammensetzungen enthaltend nsaid und gallensaeuren
De Boer et al. Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease
US6218366B1 (en) Method for raising the hypoxic threshold
Yau et al. Vitamin E for coronary bypass operations: a prospective, double-blind, randomized trial
JP7210542B2 (ja) Ｃｔイメージング用のヨウ素化脂肪酸のナノエマルジョン
JP2001515864A (ja) 非天然ｆｐ選択的作用薬を使用した骨体積増加方法
AU2003286546B2 (en) Method to treat chronic heart failure and/or elevated cholesterol levels
Lazarus et al. Extra-gastrointestinal effects of secretin, gastrin, and pancreozymin
Tangphao et al. Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia
JP2020500884A (ja) イメージング剤および使用の方法
JPH0710761A (ja) 腎性骨異栄養症における骨量減少抑制剤
JP2002537325A (ja) ＮＦ−κＢの活性化を阻害することにより治療上の影響を与えることができる、ヒトおよび動物における病気を治療するための医薬を製造するためのＲ−アリールプロピオン酸の使用
Lustig et al. Liver damage in acute self-induced hypermanganemia
EP1769793A1 (en) Therapeutic or preventive drug for diabetes, obesity, or arteriosclerosis
US20050159490A1 (en) Method to treat chronic heart failure and/or elevated cholesterol levels
US10617641B2 (en) Composition for preventing or treating ischemic diseases, containing liposomes in which VEGF-derived peptides are supported
US20220387364A1 (en) Methods to decrease triglyceride synthesis in the liver
JPS61501567A (ja) 動脈硬化の予防および治療方法
CN121796375A (zh) 用于预防和治疗糖尿病心肌病的化合物及其应用
JPS6391323A (ja) 抗尿路結石症剤
RU2257208C1 (ru) Фармацевтическая композиция, обладающая гепатозащитным действием, и лекарственное средство
CN119564664A (zh) 异佛司可林在制备治疗糖尿病心肌病药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100803